Critical Limb Ischemia
Tóm tắt
Từ khóa
Tài liệu tham khảo
Criqui MH, Langer RD, Fronek A, et al.: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992, 326:381–386.
Hirsch AT, Hartman L, Town RJ, Virnig BA: National health care costs of peripheral arterial disease in the Medicare population. Vasc Med 2008, 13:209–215.
McKenna M, Wolfson S, Kuller L: The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991, 87:119–128.
Murabito JM, Evans JC, Nieto K, et al.: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002, 143:961–965.
Howell MA, Colgan MP, Seeger RW, et al.: Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg 1989, 9:691–696; discussion 696–697.
Adam DJ, Beard JD, Cleveland T, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005, 366:1925–1934.
Stoyioglou A, Jaff MR: Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol 2004, 15:1197–1207.
Steg PG, Bhatt DL, Wilson PW, et al.: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297:1197–1206.
Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I: The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord 2005, 5:14.
Norgren L, Hiatt WR, Dormandy JA, et al.: TASC II Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45(Suppl S):S5–S67.
DeRubertis BG, Faries PL, McKinsey JF, et al.: Shifting paradigms in the treatment of lower extremity vascular disease: a report of 1000 percutaneous interventions. Ann Surg 2007, 246:415–422; discussion 422–424.
Goodney PP, Beck AW, Nagle J, et al.: National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg 2009, 50:54–60.
Hirsch AT, Haskal ZJ, Hertzer NR, et al.: American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006, 113:e463–e654.
Price JF, Mowbray PI, Lee AJ, et al.: Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 1999, 20:344–353.
Brass EP, Anthony R, Dormandy J, et al.: Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006, 43:752–759.
Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.
Feringa HH, Karagiannis SE, van Waning VH, et al.: The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg 2007, 45:936–943.
Schillinger M, Exner M, Mlekusch W, et al.: Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004, 25:742–748.
Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994, 308:81–106.
Antithrombotic Trialists’ Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71–86.
Mangano DT, Layug EL, Wallace A, Tateo I: Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996, 335:1713–1720.
Schanzer A, Hevelone N, Owens CD, et al.: Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. J Vasc Surg 2008, 47:774–781.
Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making. J Vasc Surg 2010 (In press).
Forbes J, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischemia of the leg (BASIL) trial: health-related quality of life, resource utilization and cost-effectiveness analysis. J Vasc Surg 2010 (In press).
Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg 2010 (In press). This article discusses long-term follow-up in the BASIL trial by treatment received.
Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a description of the severity and extent of disease using the Bollinger angiogram scoring method and the TASC II classification. J Vasc Surg 2010 (In press).
Bradbury A, Adam DJ, Bell J, et al.: Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: an intention to treat analysis of amputation free and overall survival in patients randomised to a bypass surgery first or a balloon angioplasty first strategy. J Vasc Surg 2010 (In press). This article discusses long-term follow-up in the BASIL trial by treatment assigned.
Conte MS: BASIL and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. J Vasc Surg 2010 (In press).
Kasapis C, Henke PK, Chetcuti SJ, et al.: Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J 2009, 30:44–55.
Stoner MC, Defreitas DJ, Manwaring MM, et al.: Cost per day of patency: understanding the impact of patency and reintervention in a sustainable model of healthcare. J Vasc Surg 2008, 48:1489–1496.
Conte MS, Bandyk DF, Clowes AW, et al.: Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006, 43:742–751; discussion 751.
Cronenwett JL, Likosky DS, Russell MT, et al.: A regional registry for quality assurance and improvement: the Vascular Study Group of Northern New England (VSGNNE). J Vasc Surg 2007, 46:1093–1101; discussion 101–102.
Conte MS, Bandyk DF, Clowes AW, et al.: Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg 2005, 42:456–464; discussion 464–465.
Goodney PP, Likosky DS, Cronenwett JL: Predicting ambulation status one year after lower extremity bypass. J Vasc Surg 2009, 49:1431–9 e1.
Goodney PP, Nolan BW, Schanzer A, et al.: Factors associated with amputation or graft occlusion 1 year after lower extremity bypass in northern New England. Ann Vasc Surg 2010, 24:57–68.
Schanzer A, Goodney PP, Li Y, et al.: Validation of the PIII CLI risk score for the prediction of amputation-free survival in patients undergoing infrainguinal autogenous vein bypass for critical limb ischemia. J Vasc Surg 2009, 50:769–775; discussion 775.
Goodney PP, Nolan BW, Schanzer A, et al.: Factors associated with death 1 year after lower extremity bypass in northern New England. J Vasc Surg 2010, 51:71–78.
Nguyen LL, Brahmanandam S, Bandyk DF, et al.: Female gender and oral anticoagulants are associated with wound complications in lower extremity vein bypass: an analysis of 1404 operations for critical limb ischemia. J Vasc Surg 2007, 46:1191–1197.
Schanzer A, Hevelone N, Owens CD, et al.: Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg 2007, 46:1180–1190; discussion 1190.
Conte MS, Geraghty PJ, Bradbury AW, et al.: Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009, 50:1462–73.e3.
Nguyen LL, Moneta GL, Conte MS, et al.: Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. J Vasc Surg 2006, 44:977–983; discussion 983–984.
Nguyen LL, Hevelone N, Rogers SO, et al.: Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. Circulation 2009, 119:123–130.
Berceli SA, Hevelone ND, Lipsitz SR, et al.: Surgical and endovascular revision of infrainguinal vein bypass grafts: analysis of midterm outcomes from the PREVENT III trial. J Vasc Surg 2007, 46:1173–1179.
Albers M, Romiti M, Brochado-Neto FC, et al.: Meta-analysis of popliteal-to-distal vein bypass grafts for critical ischemia. J Vasc Surg 2006, 43:498–503.
Schanzer A, Mega J, Meadows J, et al.: Risk stratification in critical limb ischemia: derivation and validation of a model to predict amputation-free survival using multicenter surgical outcomes data. J Vasc Surg 2008, 48:1464–1471.
Conte MS, Lorenz TJ, Bandyk DF, et al.: Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovasc Surg 2005, 39:15–23.
Ubbink DT, Vermeulen H: Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2003, CD004001.
Labropoulos N, Leon Jr LR, Bhatti A, et al.: Hemodynamic effects of intermittent pneumatic compression in patients with critical limb ischemia. J Vasc Surg 2005, 42:710–716.
Kavros SJ, Delis KT, Turner NS, et al.: Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up. J Vasc Surg 2008, 47:543–549.
Sneider EB, Nowicki PT, Messina LM: Regenerative medicine in the treatment of peripheral arterial disease. J Cell Biochem 2009, 108:753–761.
Powell RJ, Simons M, Mendelsohn FO, et al.: Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008, 118:58–65.
Nikol S, Baumgartner I, Van Belle E, et al.: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008, 16:972–978.
Rajagopalan S, Mohler 3rd ER, Lederman RJ, et al.: Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003, 108:1933–1938.
Makinen K, Manninen H, Hedman M, et al.: Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002, 6:127–133.
Kusumanto YH, van Weel V, Mulder NH, et al.: Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006, 17:683–691.
Tateishi-Yuyama E, Matsubara H, Murohara T, et al.: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427–435.
Lenk K, Adams V, Lurz P, et al.: Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. Eur Heart J 2005, 26:1903–1909.
Tepe G, Schmitmeier S, Speck U, et al.: Advances on drug-coated balloons. J Cardiovasc Surg (Torino) 2010, 51:125–143.
Scheller B, Speck U: Potential solutions to the current problem: coated balloon. EuroIntervention 2008, 4:C63–C66.
Tepe G, Zeller T, Albrecht T, et al.: Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008, 358:689–699.
Bosiers M, Peeters P, D’Archambeau O, et al.: AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol 2009, 32:424–435.
Laird JR, Zeller T, Gray BH, et al.: Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther 2006, 13:1–11.
Bosiers M, Deloose K, Verbist J, Peeters P: Nitinol stenting for treatment of ‘below-the-knee’ critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation. J Cardiovasc Surg 2007, 48:455–461.
DeRubertis BG, Pierce M, Ryer EJ, et al.: Reduced primary patency rate in diabetic patients after percutaneous intervention results from more frequent presentation with limb-threatening ischemia. J Vasc Surg 2008, 47:101–108.
Giles KA, Pomposelli FB, Spence TL, et al.: Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg 2008, 48:128–136.
Romiti M, Albers M, Brochado-Neto FC, et al.: Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008, 47:975–981.
Robinson 3rd WP, Owens CD, Nguyen LL, et al.: Inferior outcomes of autogenous infrainguinal bypass in Hispanics: an analysis of ethnicity, graft function, and limb salvage. J Vasc Surg 2009, 49:1416–1425.
Owens CD, Ho KJ, Kim S, et al.: Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg 2007, 45:944–952.
Biancari F, Salenius JP, Heikkinen M, et al.: Risk-scoring method for prediction of 30-day postoperative outcome after infrainguinal surgical revascularization for critical lower-limb ischemia: a Finnvasc registry study. World J Surg 2007, 31:217–225; discussion 226–227.
Rossi PJ, Skelly CL, Meyerson SL, et al.: Redo infrainguinal bypass: factors predicting patency and limb salvage. Ann Vasc Surg 2003, 17:492–502.
Toursarkissian B, D’Ayala M, Stefanidis D, et al.: Angiographic scoring of vascular occlusive disease in the diabetic foot: relevance to bypass graft patency and limb salvage. J Vasc Surg 2002, 35:494–500.
Alback A, Biancari F, Saarinen O, Lepantalo M: Prediction of the immediate outcome of femoropopliteal saphenous vein bypass by angiographic runoff score. Eur J Vasc Endovasc Surg 1998, 15:220–224.
Simons J, Goodney PG, Nolan B, et al.: Failure to achieve clinical improvement despite graft patency in patients undergoing lower extremity bypass for critical limb ischemia. J Vasc Surg 2010 (In press).